Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Oct;5(10):1644-8.
doi: 10.1097/JTO.0b013e3181ec1713.

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)

Gregory A Otterson  1 , Lydia Hodgson, Herbert Pang, Everett E Vokes; Cancer and Leukemia Group B
Affiliations
Clinical Trial

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)

Gregory A Otterson et al. J Thorac Oncol. 2010 Oct.

Abstract

Introduction: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin in chemosensitive recurrent SCLC based on preclinical data that suggested this to be an active target.

Methods: Patients had recurrent chemosensitive SCLC (relapse ≥90 days since completion of platinum-based chemotherapy). Treatment was administered as weekly infusions of Romidepsin at 13 mg/m(2) for 3 of 4 weeks. We designed a two-stage phase II study targeting a response rate of 30% (<10% response would be uninteresting and ≥30% worthy of further study).

Results: Sixteen patients (10 male, 6 female) were accrued to the first stage of this study. Most (11 patients, 69%) presented with extensive-stage SCLC, and all had received prior chemotherapy, with 11 having received prior radiation. Eastern Cooperative Oncology Group performance status was excellent with 0 in 6 patients (38%) and 1 in 10 patients. No objective responses were seen, and stable disease was the best response seen in 3 patients (19%). Toxicity was modest with 3 patients suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and one patient with grade 4 thrombocytopenia. Median progression-free survival was 1.8 months, and median overall survival was 6 months.

Conclusion: Romidepsin given on a weekly schedule in patients with chemosensitive, recurrent SCLC was inactive and will not be pursued further in this setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Top shows Kaplan Meier curve for Overall Survival (median 6 months) and bottom shows Kaplan Meier curve for Progression Free Survival (median 1.8 months).
Figure 1
Figure 1
Top shows Kaplan Meier curve for Overall Survival (median 6 months) and bottom shows Kaplan Meier curve for Progression Free Survival (median 1.8 months).
See this image and copyright information in PMC

References

    1. Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. - PubMed
    1. Murray N, Turrisi AT., 3rd A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006;1(3):270–8. - PubMed
    1. Cheng S, et al. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2007;2(4):348–54. - PubMed
    1. Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007;25(26):4137–45. - PubMed
    1. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355–67. - PubMed

Publication types

MeSH terms